

1 **Are serum thrombomodulin and interleukin-8 levels associated with disease**
2 **severity and mortality in critically ill children with respiratory failure?**

3
4 **Dilan AKGÜN ÜNLÜ^{1, *}, Hazal Ceren TUĞRUL², Selen Ceren ÇAKMAK¹,**
5 **Gürkan ATAY², Seher ERDOĞAN²**

6
7 ¹ Department of Pediatrics, Health Science University, Umraniye Research and Training
8 Hospital, İstanbul, Türkiye

9 ² Department of Pediatric Critical Care, Health Science University, Umraniye Research
10 and Training Hospital, İstanbul, Türkiye

11
12 ***Correspondence:** dilanakg@gmail.com

13
14 **ORCID:**

15 Dilan AKGÜN ÜNLÜ: <https://orcid.org/0009-0009-9791-5664>

16 Hazal Ceren TUĞRUL: <https://orcid.org/0000-0003-4990-0408>

17 Selen Ceren ÇAKMAK: <https://orcid.org/0000-0003-1485-3664>

18 Gürkan ATAY: <https://orcid.org/0000-0002-0317-5872>

19 Seher ERDOĞAN: <https://orcid.org/0000-0002-3393-3363>

20
21 **Acknowledgment:** The study was funded by University of Health Science Scientific
22 Research Project Unit with the project number 2023/21.

23 **Conflict of Interest:** No conflict of interest was declared by the authors.

24 **Ethical approval:** The study was approved by the local ethical committee in Health
25 Sciences University Umraniye Training and Research Hospital

1 (B.10.1.THK.4.34.H.GP.0.01/51) and complied with the Declaration of Helsinki and its
2 later amendments.

3 **Informed consent:** Informed consent was obtained from all individual participants
4 included in the study.

5

6 **Abstract**

7 **Background/aim:** Thrombomodulin (TM) is found on the endothelial cell surface and
8 increases in response to endothelial injury of different organs. Interleukin-8 (IL-8)
9 regulates pulmonary inflammation. They are candidates for a biological marker of acute
10 respiratory distress syndrome (ARDS). The aim of the present study was to compare
11 TM and IL-8 levels in pediatric patients with and without ARDS who received
12 respiratory support and to determine its relationship with prognosis.

13 **Materials and methods:** This was a prospective observational study of 55 patients who
14 received respiratory support at Pediatric Intensive Care Unit were examined. 18 patients
15 without active infection were defined as the control group. Two blood samples were
16 taken for serum IL-8 and TM levels on the first and third days of respiratory support.

17 **Results:** The patient group had significantly higher IL-8 and TM levels than the control
18 group [IL-8: median 102.7 (IQR,180.42 - 189.47) vs. 45.4 (70.49 - 55.14) ng/L, $p =$
19 0.011, respectively. TM: median 6.9 (9.18 - 6.83) vs. 3.4 (5.05 - 3.62) ng/mL, $p = 0.021,$
20 respectively]. Patients with ARDS had significantly higher markers levels on the first
21 and third days than those who did not have ARDS.

22 The TM and IL-8 levels of the deceased patients were significantly higher than those of
23 the survivors on the first day.

1 In mortality prediction, the cut-off point for IL-8 was found to be > 154.7 ng/L, which
2 had a sensitivity of 76.9% and a specificity of 73.8%. The cut-off point for TM was
3 found as > 8.4 ng/mL, which had a sensitivity of 76.9% and a specificity of 66.7%.

4 **Conclusion:** In our study, higher markers were correlated to impaired oxygenation and
5 higher mortality. Higher TM and IL-8 levels in ARDS might reflect the degree of
6 vascular injury and inflammation.

7 **Key words:** Acute Respiratory Distress Syndrome, Interleukin-8, Thrombomodulin

8 **1. Introduction**

9 Acute respiratory distress syndrome (ARDS) refers to acute lung injury affecting both
10 lungs, which results from the disruption of the alveolocapillary membrane and is
11 characterized by diffuse infiltration of the lungs [1]. Lung injury and inflammation
12 become widespread with cytokine activation and the release of proinflammatory
13 mediators [2]. It has been shown that the interleukin-8 (IL-8) level measured at the
14 beginning of ARDS is correlated to a worse prognosis and increased mortality [3,4].
15 Thrombomodulin (TM) is found on endothelial cell surface and increases in response to
16 endothelial injury of different organs. However, it is mostly expressed in the lungs.
17 Increased plasma TM level reflects inflammation, endothelial injury, and a tendency to
18 thrombosis [5]. TM is a biological candidate marker for respiratory failure and ARDS.
19 Our primary aim in conducting the present study was to compare TM and IL-8 levels in
20 pediatric patients with respiratory failure with or without ARDS who were provided
21 with respiratory support with mechanical ventilation, and to determine their relationship
22 with prognosis. Our secondary aim was to evaluate the relationship between the levels
23 of TM, IL-8 and the oxygenation index (OI), extrapulmonary organ failure, number of
24 days on mechanical ventilator, and the number of days spent in Pediatric Intensive Care

1 Unit (PICU), and also to compare IL-8 and TM levels in patient groups with or without
2 ARDS to determine whether they are risk factors for developing ARDS.

3 **2. Materials and methods**

4 **2.1. Study design**

5 A total of 55 patients, including 34 patients receiving invasive mechanical ventilator
6 (IMV) support and 21 patients receiving noninvasive mechanical ventilator (NIMV)
7 support due to respiratory failure lasting longer than 72 hours in the Pediatric Intensive
8 Care Unit of Health Sciences University Umraniye Training and Research Hospital
9 between March 2022 and December 2022, were included in the single-center and
10 prospective study.

11 Eighteen patients without active infection were defined as the control group. The study
12 was approved by the local ethical committee in Health Sciences University Umraniye
13 Training and Research Hospital (B.10.1.THK.4.34.H.GP.0.01/51) and complied with the
14 Declaration of Helsinki and its later amendments. The Informed consents of the patients
15 and control groups were obtained.

16 **2.2. Data and blood sample collection**

17 The clinical, demographic, and laboratory data of the patients were recorded.

18 The pediatric risk score of mortality (PRISM) of patients started on ventilator support for
19 respiratory failure was calculated at the first 24 hours of treatment while the organ failure
20 index (OFI) and pediatric logistic organ score (PELOD) were calculated at 24th and 72nd
21 hours of treatment.

22 Saturation / FiO_2 (S/F) ratio was calculated in patients who received non-invasive
23 respiratory support, saturation index (OSI: $(\text{FiO}_2 \times \text{mean airway pressure} \times 100 / \text{SpO}_2)$
24 in those who received invasive mechanical ventilation support, and vasoactive inotrope

1 score (VIS) in those who received inotropic drug support at 24th and 72nd hours of
2 treatment. The relationship between ARDS development and IL-8 and TM levels was
3 evaluated on the first and third days of respiratory support. Immunosuppressed patients,
4 patients using corticosteroids (at a dose of more than 1 mg/kg/day for longer than 1
5 month), and patients with missing medical records were excluded.

6 IL-8 and TM kits were studied at Farmasina Medical and Chemical Products Industries
7 and Foreign Trade Ltd. Co. using a ELX800DA model Diagnostic Automation Inc.
8 device and the KC junior program. Venous blood samples were taken for serum IL-8 and
9 TM levels at 24th and 72nd hours of respiratory support treatment, simultaneously with
10 the samples taken for other tests. After the samples were centrifuged at 4000 rpm for 10
11 minutes, their sera were separated into an Eppendorf tube and stored at -80 ° until
12 biochemical analyses. Venous blood samples obtained from the control group were also
13 centrifuged and stored at -80°.

14 **2.3. Statistical Methods**

15 Statistical analyses were performed using IBM SPSS Statistics 22 software. Normality of
16 distribution of the study parameters was tested using Kolmogorov-Smirnov test.
17 Descriptive statistics included mean, standard deviation, and frequency. Non-normally
18 distributed continuous variables were compared between the study groups using Kruskal
19 Wallis test. Student's t test was used to compare normally distributed parameters between
20 the two groups while Mann Whitney-U test was used to compare non-normally
21 distributed parameters. Categorical parameters were compared using Fisher's Exact Chi-
22 Square and Continuity (Yates) Correction. Multivariate analysis was carried out with
23 logistic regression analysis. When the effects of NIMV/MV, sepsis, ARDS, inotrope
24 requirement, days of PICU stay, first day IL-8 and TM levels, 1st and 3rd day PRISM,

1 PELOD, OFI, OSI scores, 3rd day total protein, C-reactive protein (CRP), procalcitonin
2 (PCT) levels, 1st and 3rd day platelet (PLT) levels on mortality were evaluated by
3 Backward stepwise logistic regression analysis; the model was found to be significant. (p
4 = 0.001; $p < 0.05$). The Nagelkerke R square level was 0.755 and the explanatory
5 coefficient of the model (88.2%) was found to be at a good level. When we
6 The best cut-off points were determined using the ROC curve analysis. Pearson
7 correlation analysis was used to test correlations between normally distributed
8 parameters; Spearman's rho correlation analysis was used to test correlations between
9 non-normally distributed parameters. Statistical significance was set at $p < 0.05$.

10 **3. Results**

11 **3.1. Baseline characteristics of patients**

12 The study was performed with a total of 55 patients, 52.7% ($n = 29$) females and 47.3%
13 ($n = 26$) males, aged between 1 month and 17 years. The mean age of the patients was
14 64.16 ± 66.21 months. 38.2% ($n = 21$) of patients received respiratory support with NIMV
15 and 61.8% ($n = 34$) of patients received respiratory support with IMV. Clinical
16 characteristics of the patients are summarized in Table 1. Clinical signs of sepsis and
17 ARDS were present in 54.5% ($n = 30$) and 29.1% ($n = 16$) of the patients, respectively.
18 ARDS was mild in 12.5%, moderate in 43.8% and severe in 43.8% of patients. The
19 etiology of patients with ARDS included respiratory failure, sepsis and
20 bronchopneumonia, whereas patients without ARDS included MISC, cardiac diseases,
21 neurological diseases and sepsis. An underlying disease was found in 81.8% ($n = 45$) of
22 the patients. 47.3% ($n = 26$) of the patients were admitted to the PICU for respiratory
23 failure. 72.7% ($n = 40$) of patients underwent blood product transfusions. Failure of an
24 organ was present in 49.1% of patients, failure of two organs in 38.2%, failure of three

1 organs in 10.9%, and failure of 4 organs in 1 patient. 27.3% patients needed inotropic
2 drug infusion. The survival rate of the patients was 76.4%. The patient and control groups
3 were compared with respect to age and sex, and no significant difference was found
4 between the two groups.

5 **3.2. Parameters changing between 24th and 72nd hours**

6 Table 2 presents comparison of the patients' biochemical and blood gas parameters and
7 scores on the first and third days. The decrease in CRP, PCT, white blood cell count
8 (WBC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea,
9 creatinine, lactate, and partial carbon dioxide pressure (PaCO₂) seen on the third day
10 compared to the first day was statistically significant. Significant differences were also
11 found in the PRISM, PELOD, OFI, OSI scores on the third day compared with the first
12 day.

13 **3.3. Serum levels of IL-8 and TM**

14 IL-8 and TM levels of the patient group were significantly higher than those of the
15 control group [IL-8: median 102.7 (IQR,180.42 - 189.47) vs. 45.4 (70.49 - 55.14) ng/L,
16 p = 0.011, respectively. TM: median 6.9 (9.18 - 6.83) vs. 3.4 (5.05 - 3.62) ng/mL, p =
17 0.021, respectively]. As shown in Figure 1 and Figure 2, serum IL-8 and TM levels on
18 the 3rd day were significantly lower than those on the 1st day. There was no significant
19 difference between the patients who received NIMV and those who received IMV with
20 respect to the IL-8 and TM levels on the first and third days. As presented in Table 3,
21 both IL-8 and TM levels of the patients with ARDS were significantly higher than those
22 of patients without ARDS. IL-8 levels on the first and third days of patients with ARDS
23 were median 176.6 (303.75 ± 223.08) - 90.2 (118 ± 76.55) ng/L, respectively and IL-8
24 levels on the first and third days of patients without ARDS were 61.5 (129.82 ± 149.46)

1 - 43.2 (85.64 ± 93.62) ng/L, respectively. TM levels on the first and third days of
2 patients with ARDS were 12.3 (13.85 ± 6.81) - 7.2 (9.42 ± 6.49) ng/mL, respectively
3 and TM levels on the first and third days of patients without ARDS were 4.1 (7.26 ±
4 5.92) - 3.3 (5.4 ± 4.85) ng/mL, respectively. There was no significant difference
5 between the IL-8 and TM levels by the presence of sepsis and the ARDS classification.
6 No significant difference was found between the IL-8 and TM levels on the first and
7 third days of the patients with and without sepsis.

8 **3.4. Performance of biomarkers in predicting mortality**

9 Table 4 presents comparison of the patients' clinical characteristics and laboratory
10 parameters by their prognosis. There was a significant, positive relationship of moderate
11 degree between the IL-8 level on the first day and the number of failed organs, PELOD
12 score, and AST level. There was a moderately strong, positive correlation between the
13 TM level on the first day and the number of failed organs, AST and activated partial
14 thromboplastin time (aPTT). There was a weak, negative correlation between the TM
15 level on the first day and the levels of albumin, total protein. The deceased patients had
16 a significantly higher TM level on the first day than the survivors; no significant
17 difference was found between the TM levels on the third day.

18 As compared with the surviving patients, the deceased patients had a higher number of
19 days spent in PICU and on NIMV/IMV, PRISM, PELOD, OSI, OFI scores, and CRP and
20 PCT levels on the third day although they had a lower total protein level on the third day
21 and a lower PLT on the first and third days. The two groups had no significant difference
22 with respect to other parameters. Risk factors affecting mortality are presented in Table
23 5. A logistic regression analysis was performed to determine the risk factors affecting
24 mortality. The effects of the IL-8 level on the first day, PLT on the third day, OFI score

1 on the first day, and OSI score on the first day had statistically significant effects on the
2 model. Mortality risk was increased by 1.017-fold by a high IL-8 on the first day, 0.972-
3 fold by a low PLT on the third day, 11.418 folds by a high OFI score on the first day, and
4 2.733 folds by a high OSI score on the first day. As shown in Figure 3, according to the
5 ROC analysis, the area under the curve (AUC) of IL-8 level was found to be 0.723 (95%
6 CI:0.558-0.888). The cut-off point of IL-8 level for mortality prediction was found as >
7 154.7 ng/L. This cut-off value had a sensitivity of 76.9% and a specificity of 73.8%. As
8 shown in Figure 4, according to the ROC analysis, the area under the curve (AUC) of TM
9 level was found to be 0.715 (95% CI:0.542 - 0.882). The cut-off point of TM level for
10 mortality prediction was found as > 8.4 ng/mL. This cut-off value was found to have a
11 sensitivity of 76.9% and a specificity of 66.7%.

12 **4. Discussion**

13 Thrombomodulin is an endothelial and pulmonary capillary transmembrane protein,
14 which has an active role in coagulation and inflammation. Its circulating level is normally
15 very low but increases in inflammatory conditions such as sepsis or ARDS [6]. It is a
16 candidate biological marker for respiratory failure and ARDS. TM plays an important
17 role in the development of the lungs; it increases in response to endothelial injury of
18 different organs, although it is most commonly expressed in the lungs. In a study
19 conducted in adults with acute respiratory distress, increased TM level was shown to be
20 correlated to a higher mortality [7].

21 In a study involving 432 pediatric patients treated with invasive mechanical ventilation
22 for acute respiratory failure, Monteiro et al. [8] reported that TM level ranged between
23 16.6 and 670.9 ng/mL in the first 5 days of intubation, and an increased TM level was
24 associated with an increased 90- day mortality rate and a worse OI. They also reported

1 that both initial TM level and TM level during follow-up were correlated to
2 extrapulmonary multiorgan failure risk and the severity of hypoxic respiratory failure,
3 and that increased TM level reflected increased dead space ventilation in patients with
4 ARDS. These findings suggested that vascular injury plays a role in the pathogenesis of
5 acute respiratory failure, and it can provide a potential contribution to the determination
6 of treatment targets. Our study also showed that TM level measured in the first 3 days of
7 intubation was significantly higher in patients with ARDS (12.3 (13.85 ± 6.81) vs 7.2
8 (9.42 ± 6.49) ng/mL) who underwent invasive mechanical ventilation compared with
9 patients without ARDS (4.1 (7.26 ± 5.92) vs 3.3 (5.4 ± 4.85) ng/mL).

10 Orwoll et al. [9], in a prospective study involving 243 pediatric patients diagnosed with
11 lung injury, reported that increased sTM level was associated with increased mortality
12 and a greater rate of organ dysfunction. In accordance with the literature, our study found
13 a moderately strong (44%), positive, and statistically significant correlation between
14 increased TM level and the number of failed organs. Similarly, TM level measured at
15 24th hour was correlated to an increased mortality rate (Figure 2).

16 A study published in 2017, which was conducted in previously healthy pediatric patients
17 admitted to PICU for septic shock, reported that TM levels measured on the first and third
18 days were significantly higher in the patient group than the healthy control group.
19 Similarly, the deceased patients had a significantly higher TM level than the survivors
20 (9.9 mU/mL vs 4.4 mU/mL, $p = 0.046$). There was a positive correlation between serum
21 thrombomodulin level and PRISM, PELOD, P-MODS, and disseminated intravascular
22 coagulation (DIC) scores on the first day [10]. Similarly, our study found that the patient
23 group had a significantly higher TM level on the first day than the control group (6.9
24 (9.18 - 6.83) vs. 3.4 (5.05 - 3.62) ng/mL, respectively, $p = 0.021$). However, no significant

1 correlation was found between TM level and the PRISM, PELOD, OFI scores on the first
2 day, and sepsis.

3 Previous animal experiments have shown that recombinant TM shows a protective effect
4 in septic mice by suppressing leukocyte adhesion in the microvascular space, reducing
5 thrombus formation, and preventing endothelial injury [11]. Data from another study in
6 mice suggested that TM has protective properties in LPS-mediated ARDS [12].

7 Randomized controlled studies on adult patients with DIC have compared treatment with
8 recombinant sTM and heparin; it has been reported that treatment with TM has provided
9 a better improvement [13]. In a study on pediatric patients with acute respiratory failure
10 who were intubated and provided respiratory support with mechanical ventilation,
11 Carlton et al. reported that there was no significant correlation between functional
12 deterioration and serum IL-8 and thrombomodulin levels on the first day of intubation,
13 but serum thrombomodulin level was higher on the second and third days in patients with
14 a deteriorated but serum thrombomodulin level was higher on the second and third days
15 in patients with a deteriorated functional status than those without [14].

16 IL-8 secretion is induced by TNF and IL-1, which are classical proinflammatory
17 cytokines secreted in the early stages of inflammation. IL-8 is secreted by pulmonary
18 endothelial cells in injuries caused by toxins or infections. It was determined that IL-8
19 concentration in bronchoalveolar lavage was 5-10 folds higher in intubated patients
20 compared with the control group [15]. A correlation was shown between increased IL-8
21 levels in both plasma and bronchoalveolar lavage fluid and death and multiorgan failure
22 in adult ARDS patients [16]. It is considered that serially measured IL-8 levels can be
23 used as a marker of treatment efficacy in pediatric patients with sustained inflammation,
24 particularly those with ARDS and respiratory failure. In a multicenter study dated 2017,

1 which was conducted by Zinter et al. on pediatric ARDS patients, it was determined that
2 IL-6, IL-8, IL-10, and TNF-R2 were strongly correlated to mortality, and there was a
3 positive correlation between these biomarkers and OI and PRISM scores [17]. Our study
4 found significantly higher IL-8 levels in the patient group than the control group (IL-8:
5 median 102.7 (180.42 ± 189.47) – 45.4 (70.49 ± 55.14) ng/L, respectively p = 0.001).
6 Serum IL-8 level measured on the first day was significantly higher in patients with
7 ARDS than those without (176.6 (303.75 ± 223.08) - 61.5 (129.82 ± 149.46) ng/ L,
8 respectively, p = 0.001).

9 Flori et al. conducted a prospective study on pediatric patients intubated for respiratory
10 failure. In that study, which was conducted in 22 pediatric intensive care units on 480
11 patients, the authors aimed to evaluate the relationship between plasma IL-8 level
12 measured serially in the early stage and ARDS development and the other markers of
13 prognosis in pediatric patients mechanically ventilated for acute respiratory failure. They
14 reported that the highest IL-8 level was determined on the first day of intubation, and IL-
15 8 level gradually decreased during follow-up. An analysis based on patient subgroups
16 revealed the highest levels in the sepsis group and the lowest level in the asthma group.
17 Serum IL-6 level was highest in patients with ARDS than those without. Similarly, it was
18 reported that serum IL-8 level was 4-12 folds higher in deceased patients compared with
19 the surviving ones. Serum IL-8 level was significantly correlated to mortality, duration
20 of mechanical ventilation, and the number of days spent in PICU, but not ARDS
21 development [18]. In our study, patients with respiratory failure were provided with
22 respiratory support by means of NIMV or IMV. No significant difference was found
23 between patients treated with NIMV or IMV regarding the IL-8 levels on the first and
24 third days. Unlike other studies, IL-8 level was found to be significantly higher in patients

1 who developed ARDS. The highest IL-8 level was observed on the first day of intubation
2 (180.4 ng/L); a decrease occurred on the 3rd day (95.05 ng/L). There was no significant
3 difference between patients with or without sepsis. No significant correlation was found
4 between the number of days spent in PICU and serum IL-8 level.

5 The limitations of our study include its single-center design, and the lack of the evaluation
6 the relationship between viral and bacterial pathogens detected by respiratory tract viral
7 multiplex examination and tracheal aspirate culture proliferations and serum TM and IL-
8 8 levels. Another limitation of our study is that the results cannot be generalized to the
9 immunocompromised patient population because they were excluded from the study.

10 **5. Conclusion**

11 In conclusion, higher TM and IL-8 levels in pediatric patients who received invasive and
12 non-invasive respiratory support for respiratory failure were found to be correlated to
13 impaired oxygenation, higher mortality, and a higher number of failed organs. Higher TM
14 and IL-8 levels in ARDS might reflect the degree of vascular injury and inflammation. A
15 gradual decline in IL-8 and TM levels during the patients' follow-up suggests that these
16 parameters can be used as biomarkers both for determining treatment objective and
17 predicting prognosis. However, larger studies are needed to use TM and IL-8 as
18 biomarkers.

19 **References**

- 20 1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults.
21 *Lancet*. 1967; 2 (7511): 319-323. [https://doi.org/10.1016/S0140-6736\(67\)90168-7](https://doi.org/10.1016/S0140-6736(67)90168-7)
- 22 2. Kaku S, Nguyen CD, Htet NN, Tintera D, Barr J et al. Acute Respiratory Distress
23 Syndrome: Etiology, Pathogenesis, and Summary on Management. *Journal of Intensive*
24 *Care Medicine* 2020; 35 (8): 723-737. <https://doi.org/10.1177/0885066619855021>

- 1 3. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of
2 healthy subjects. *Mediators of Inflammation* 2013; 2013: 434010.
3 <https://doi.org/10.1155/2013/434010>
- 4 4. Haugen J, Chandyo RK, Brokstad KA, Mathisen M, Ulak M et al. Cytokine
5 Concentrations in Plasma from Children with Severe and Non-Severe Community
6 Acquired Pneumonia. *Plos One*. 2015; 10 (9): e0138978.
7 <https://doi.org/10.1371/journal.pone.0138978>
- 8 5. Conway EM. Thrombomodulin and its role in inflammation. *Seminars in*
9 *Immunopathology*. 2012; 34 (1): 107-125. <https://doi.org/10.1007/s00281-011-0282-8>
- 10 6. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular
11 endothelium: insights into functional, regulatory, and therapeutic aspects. *American*
12 *Journal of Physiology Heart and Circulatory Physiology*. 2013; 304 (12): H1585-597.
13 <https://doi.org/10.1152/ajpheart.00096.2013>
- 14 7. Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H et al. Plasma soluble
15 thrombomodulin levels are associated with mortality in the acute respiratory distress
16 syndrome. *Intensive Care Medicine*. 2015; 41 (3): 470-478.
17 <https://doi.org/10.1007/s00134-015-3648-x>
- 18 8. Monteiro ACC, Flori H, Dahmer MK, Sim MS, Quasney MW et.al. Thrombomodulin
19 is associated with increased mortality and organ failure in mechanically ventilated
20 children with acute respiratory failure: biomarker analysis from a multicenter randomized
21 controlled trial. *Critical Care*. 2021; 25 (1): 271. [https://doi.org/10.21203/rs.3.rs-](https://doi.org/10.21203/rs.3.rs-150966/v1)
22 [150966/v1](https://doi.org/10.21203/rs.3.rs-150966/v1)
- 23 9. Orwoll BE, Spicer AC, Zinter MS, Alkhouli MF, Khemani RG et al. Elevated soluble
24 thrombomodulin is associated with organ failure and mortality in children with acute

1 respiratory distress syndrome (ARDS): a prospective observational cohort study. *Critical*
2 *Care*. 2015; 19:435. <https://doi.org/10.1186/s13054-015-1145-9>

3 10. Lin JJ, Hsiao HJ, Chan OW, Wang Y, Hsia SH et al. Increased serum thrombomodulin
4 level is associated with disease severity and mortality in pediatric sepsis. *Plos One*. 2017;
5 12 (8): e0182324. <https://doi.org/10.1371/journal.pone.0182324>

6 11. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N et al. Efficacy and safety
7 of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular
8 coagulation: results of a phase III, randomized, double-blind clinical trial. *Journal of*
9 *Thrombosis and Haemostasis*. 2007; 5 (1): 31-41. <https://doi.org/10.1111/j.1538->
10 [7836.2006.02267.x](https://doi.org/10.1111/j.1538-7836.2006.02267.x)

11 12. Iba T, Aihara K, Watanabe S, Yanagawa Y, Takemoto M et al. Recombinant
12 thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-
13 endothelial interaction in a rat LPS model. *Thrombosis Research*. 2013; 131 (4): 295-299.
14 <https://doi.org/10.1016/j.thromres.2012.11.025>

15 13. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB et al. Effect of a
16 Recombinant Human Soluble Thrombomodulin on Mortality in Patients with Sepsis-
17 Associated Coagulopathy: The SCARLET Randomized Clinical Trial. *JAMA*. 2019; 321
18 (20): 1993- 2002. <https://doi.org/10.1001/jama.2019.5358>

19 14. Carlton EF, Weeks HM, Dahmer MK, Quasney MW, Sapru A et al. Inflammatory
20 Biomarkers Are Associated with a Decline in Functional Status at Discharge in Children
21 with Acute Respiratory Failure: An Exploratory Analysis. *Critical Care Explorations*.
22 2021; 3 (7): e0467. <https://doi.org/10.1097/CCE.0000000000000467>

23 15. Todd DA, Marsh MJ, George A, Henderson NG, Barr H et al. Surfactant
24 phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in

1 children. *Pediatric Critical Care Medicine* 2010; 11 (1): 82-91.
2 <https://doi.org/10.1097/PCC.0b013e3181ae5a4c>

3 16. Ware L, Koyama T, Zhao Z, Janz DR, Wickersham N et al. Biomarkers of lung
4 epithelial injury and inflammation distinguish severe sepsis patients with acute
5 respiratory distress syndrome. *Critical Care* 2013; 17 (5) R253.
6 <https://doi.org/10.1186/cc13080>

7 17. Zinter MS, Orwoll BE, Spicer AC, Alkhouli MF, Calfee CS et al. Incorporating
8 Inflammation into Mortality Risk in Pediatric Acute Respiratory Distress Syndrome.
9 *Critical Care Medicine* 2017; 45 (5): 858-866.
10 <https://doi.org/10.1097/CCM.0000000000002370>

11 18. Flori H, Sapru A, Quasney MW, Gildengorin G, Curley MAQ et al. A prospective
12 investigation of interleukin-8 levels in pediatric acute respiratory failure and acute
13 respiratory distress syndrome. *Critical Care*. 2019; 23 (1): 128.
14 <https://doi.org/10.1186/s13054-019-2342-8>

15
16
17
18
19
20
21
22
23
24
25
26
27

1 **Table 1:** Clinical characteristics of the patients

Study	Min-Max	Mean ± SD	Median
PICU (days)	3 - 123	24.29 ± 28.09	13
NIMV/ IMV days (n)	3 - 123	18.65 ± 25.37	8
VIS	0 - 240	9.92 ± 34.92	0
		N	%
Admission diagnosis	Respiratory Failure	26	47.3
	Sepsis	21	38.2
	MIS-C	3	5.5
	Status Epilepticus	2	3.6
	Postoperative	2	3.6
	Arrhythmia	1	1.8
Underlying disease	Yes	45	81.8
	No	10	18.2
Sepsis	Yes	25	45.5
	No	30	54.5
NIMV/ IMV	NIV	21	38.2
	IMV	34	61.8
ARDS	Yes	39	70.9
	No	16	29.1
ARDS severity (n=16)	Mild	2	12.5
	Moderate	7	43.8
	Severe	7	43.8
Blood product	No	15	27.3
	Yes	40	72.7
Number of failed organs	1	27	49.1
	2	21	38.2
	3	6	10.9
	4	1	1.8
Inotrope	No	40	72.7
	Yes	15	27.3
Mortality	Survived	42	76.4
	Deceased	13	23.6

2 PICU (days): Number of days spent at Paediatric Intensive Care Unit, NIMV/ IMV days (n): Number of
3 days on non-invasive Mechanical Ventilation/Mechanical Ventilation, VIS: Vasoactive Inotrope Score

4
5
6
7
8

1
2
3

Table 2: Comparison of the patients’ biochemical and blood gas parameters and scores on the first and third days

	1st day	3rd day	
	Mean ± SD (median)	Mean ± SD (median)	P
IL-8 (ng/L)	180.42 ± 189.47 (102.7)	95.05 ± 89.53 (70.5)	¹ 0.001*
TM (ng/mL)	9.18 ± 6.83 (6.9)	6.57 ± 5.62 (4.4)	¹ 0.001*
ALT (u/L)	128.51 ± 496.87 (28)	61.75 ± 126.54 (23)	¹ 0.046*
AST (u/L)	239.47 ± 836.26 (48)	75.31 ± 141.27 (28)	¹ 0.001*
BUN (mg/dl)	28.53 ± 28.29 (17.9)	20.57 ± 20.96 (13.6)	¹ 0.002*
Creatinine (mg/dl)	0.42 ± 0.37 (0.3)	0.35 ± 0.3 (0.2)	¹ 0.009*
Calcium (mg/dl)	8.76 ± 0.71 (8.8)	9.01 ± 0.67 (9)	¹ 0.003*
CRP (mg/L)	64.18 ± 79.64 (33)	39.14 ± 53.63 (21)	¹ 0.001*
PCT (ng/ml)	11.26 ± 24.97 (0.8)	3.25 ± 6.82 (0.5)	¹ 0.001*
WBC (10 ³ /uL)	11.82 ± 8.32 (11.5)	9.56 ± 6.41 (8.8)	¹ 0.003*
pH	7.29 ± 0.17 (7.3)	7.39 ± 0.09 (7.4)	² 0.001*
PCO ₂ (mm/Hg)	49.92 ± 20.88 (46.7)	42 ± 11.25 (40.8)	² 0.009*
HCO ₃ (mmol/L)	21.63 ± 5.88 (22.4)	24.7 ± 4.45 (24)	² 0.001*
Lactate (mmol/L)	3.22 ± 3.6 (1.8)	2.21 ± 3.73 (1.3)	¹ 0.023*
PRISM	9.42 ± 5.14 (9)	6.44 ± 5.12 (7)	0.001*
PELOD	13.67 ± 7.81 (11)	8.89 ± 6.34 (10)	0.001*
OFI	1.6 ± 1.12 (2)	1.22 ± 1.17 (1)	0.001*
OSI	9.2 ± 3.81 (9.1)	7.79 ± 4.12 (6.8)	0.024*
S/F	197.28 ± 47.82 (169)	271.24 ± 30.60 (270)	0.001*

4
5
6
7
8
9
10
11

¹Wilcoxon sign test ²Paired Samples t test *p < 0.05

ALT: Alanine Aminotransferase, AST: Aspartate amino transaminase, BUN: blood urea nitrogen, CRP: C Reactive Protein, PCT: Procalcitonin, WBC: White blood cell count, PaCO₂: Partial arterial carbon dioxide pressure, HCO₃: Bicarbonate PRISM: Paediatric Mortality Risk Scoring, PELOD: Paediatric Logistic Organ Dysfunction Score, OFI: Organ Failure Index, OSI: Oxygen Saturation Index, S/F: Saturation/FiO₂

1 **Table 3:** Comparison of the IL-8 and TM levels of the patient group

		ARDS absent	ARDS present	
		Mean ± SD (median)	Mean ± SD (median)	p
IL-8 (ng/L)	1st day	129.82 ± 149.46 (61.5)	303.75 ± 223.08 (176.6)	0.001*
	3rd day	85.64 ± 93.62 (43.2)	118 ± 76.55 (90.2)	0.020*
TM (ng/mL)	1st day	7.26 ± 5.92 (4.1)	13.85 ± 6.81 (12.3)	0.001*
	3rd day	5.4 ± 4.85 (3.3)	9.42 ± 6.49 (7.2)	0.006*

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

1 **Table 4:** Comparison of the patients' clinical characteristics and laboratory parameters
 2 by their prognosis

		Survivors	Deceased	
		Mean ± SD (median)	Mean ± SD (median)	p
Age (months)		68.9 ± 69.03 (37)	48.85 ± 55.77 (16)	¹ 0.545
Number of days on NIMV/IMV		16.12 ± 25.86 (6.5)	26.85 ± 22.75 (20)	¹ 0.002*
Number of failed Organs		1.55 ± 0.71 (1)	2 ± 0.82 (2)	¹ 0.055
IL-8 (ng/L)	1st day	150.53 ± 174.19 (67.9)	276.98 ± 211.3 (173.3)	¹ 0.016*
	3rd day	89.63 ± 93.69 (51.2)	112.56 ± 75.13 (83.1)	¹ 0.191
TM (ng/mL)	1st day	7.93 ± 6.3 (5.4)	13.2 ± 7.17 (11.8)	¹ 0.020*
	3rd day	6.09 ± 5.67 (3.7)	8.12 ± 5.4 (7.3)	¹ 0.143
PRISM score	1st day	8.62 ± 5.22 (8)	12 ± 4.06 (12)	¹ 0.013*
	3rd day	5.26 ± 4.54 (2.5)	10.23 ± 5.21 (10)	¹ 0.001*
PELOD score	1st day	12.5 ± 7.77 (11)	17.46 ± 6.92 (20)	¹ 0.008*
	3rd day	7.4 ± 6.13 (10)	13.69 ± 4.46 (12)	¹ 0.001*
OFI score	1st day	1.36 ± 1.03 (1)	2.38 ± 1.04 (2)	¹ 0.002*
	3rd day	0.93 ± 1 (1)	2.15 ± 1.21 (2)	¹ 0.001*
OSI	1st day	7.7 ± 3 (8)	11.62 ± 3.82 (12)	¹ 0.002*
	3rd day	6.18 ± 3.35 (6)	10.39 ± 4.04 (10.2)	¹ 0.003*
Total protein (g/L)	1st day	54.22 ± 11.62 (54)	50.54 ± 8.68 (51)	² 0.298
	3rd day	55.42 ± 8.81 (56)	47.8 ± 6.27 (48)	² 0.006*
C Reaktif Protein (mg/L)	1st day	64.63 ± 83.14 (30.3)	62.75 ± 70.16 (44)	¹ 0.866
	3rd day	28.86 ± 35.29 (15.5)	72.36 ± 84.39 (36.8)	¹ 0.025*
Procalcitonin (ng/ml)	1st day	7.47 ± 19.69 (0.7)	23.48 ± 35.61 (2.2)	¹ 0.061
	3rd day	2.2 ± 4.87 (0.3)	6.66 ± 10.57 (1.3)	¹ 0.011*
PLT (10 ³ /uL)	1st day	250.26 ± 138.96 (243)	148 ± 154.93 (82)	² 0.028*
	3rd day	266.81 ± 160.51 (242)	106.77 ± 95.75 (80)	² 0.001*

3 ¹Mann Whitney U Test

²Student t test

*p < 0.05

4

5

1 **Table 5:** Evaluation of risk factors affecting mortality


	OR	95% Confidence Interval		P
		Lower limit	Upper limit	
IL-8 (ng/L) (1st day)	1.017	0.999	1.034	0.047*
PCT (ng/ml) (3rd day)	0.639	0.366	1.116	0.115
PLT (10 ³ /uL) (3rd day)	0.972	0.946	0.999	0.044*
PELOD (1st day)	0.657	0.417	1.035	0.070
OFI (1st day)	11.418	0.624	209.042	0.021*
OSI (1st day)	2.733	0.887	8.418	0.040*

2 PELOD: Paediatric Logistic Organ Dysfunction Score, OFI: Organ Failure Index, OSI: Oxygen

3 Saturation Index, IL-8: Interleukin-8. PCT: Procalcitonin, PLT: Platelet

4


5



1

2

Figure 1. IL-8 levels of patients on the first and third days




1

2


Figure 2. TM levels of patients on the first and third days

1



2

3 **Figure 3.** The cut-off point determined for IL-8 level on the first day for mortality
4 prediction was > 154.7 ng/L. This level had a sensitivity of 76.9% and a specificity of
5 73.8%



1

2

3 **Figure 4.** The cut-off determined for TM on the first day for mortality prediction was >
4 8.4 ng/mL. This level had a sensitivity of 76.9% and a specificity of 66.7%.

5

6